announces

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full…

2 months ago

Euro NCAP announces 2026 protocol changes to tackle modern driving risks

LEUVEN, BELGIUM – Euro NCAP is making major changes to how it evaluates the safety of new cars to better…

2 months ago

MSI Announces ‘MSI Lucky Friday’ Sale with Exciting Deals on Gaming & Productivity Laptops

~ MSI's Black Friday offers live from 23rd to 30th November on Amazon & Flipkart ~~ Massive discounts up to…

2 months ago

PhoneX Holdings, Inc. Announces Board Change and Adoption of Long-Term Incentive Plan

New York, NY, Nov. 25, 2025 (GLOBE NEWSWIRE) -- PhoneX Holdings, Inc. (“PhoneX” or the “Company”) (OTC Pink: PXHI) today…

2 months ago

Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia

November 25, 2025 18:15 ET  | Source: Ascendis Pharma –  Prescription Drug User Fee Act (PDUFA) goal date extended by…

2 months ago

ACASPRESSO Announces Black Friday Mega Sale on Coffee and Blending Appliances

Zhuhai, Nov. 24, 2025 (GLOBE NEWSWIRE) -- ACASPRESSO, an emerging brand in the home appliance sector, has announced limited-time Black…

2 months ago

Menarini Group Announces New Data on ELZONRIS (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition

Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN)BPDCN…

2 months ago

Pennsylvania Perio & Implants Announces Strengthened Commitment to Evidence-Based Periodontal and Dental Implant Evaluation in Pennsylvania

York, Pennsylvania, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Pennsylvania Perio & Implants today announced the reinforcement of its evidence-based framework…

2 months ago

Junshi Biosciences Announces Primary Endpoints Met in JS001scs Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

2 months ago

Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Natures Signal Transduction and Targeted Therapy

Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE…

2 months ago